COURTNEY FISCHER-BROWN: Open Payments
NPI 1457627945 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$347 in 17 payments from 9 companies in 2025. Trend: 2023 $420 · 2024 $267 · 2025 $347
Food & beverage: $347
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 5 | $90 |
| PFIZER INC. | 2 | $51 |
| ABBVIE INC. | 2 | $50 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $47 |
| AstraZeneca Pharmaceuticals LP | 1 | $31 |
| Lilly USA, LLC | 1 | $22 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Novo Nordisk Inc | 1 | $18 |
Products named: REPATHA, PREVNAR 20, QULIPTA, JARDIANCE, FARXIGA, MOUNJARO, TRELEGY ELLIPTA, CONTRAVE.
Industry payments across TX — which companies pay providers there.
